Ultragenyx to sell rare pediatric disease voucher for $210 million
Tweet Send to a Friend
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




